Enoticumab
Alternative Names: Anti-Delta-Like Ligand 4 monoclonal antibody - Regeneron; Anti-DLL4 monoclonal antibody - Regeneron; REGN-421; SAR-153192Latest Information Update: 05 Nov 2023
At a glance
- Originator Regeneron Pharmaceuticals; sanofi-aventis
- Developer Regeneron Pharmaceuticals; Sanofi
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action DLL4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 31 Dec 2014 Discontinued - Phase-I for Solid tumours (Late-stage disease) in USA (IV) before December 2014 (Regeneron, Form 10-K, February 2015)
- 31 Jul 2014 Sanofi opts out of co-development agreement for Enoticumab (ADNM)
- 11 Mar 2014 Phase-I development is ongoing in USA